Learn more about the impact of psoriatic arthritis, incuding in limited joint involvement
Learn more about patient and HCP perceptions of psoriatic disease and unmet needs
Learn more about the inflammation pathways in PsA
Learn more about recognizing oral ulcers as the hallmark manifestation of Behcet's disease
Learn more about Amgen's long-standing expertise in Biologics
Learn more about developing biosimilars
Learn more about the ongoing Phase 3 study in pediatrics with active juvenille PsA
Learn more about the ongoing Phase 3 study in pediatrics with active oral ulcers in BCT dx
Learn more about GPA/MPA management and pathophysiology, including disease burden
Learn more about the BVAS, a validated tool that measures disease activity in AAV
FOREMOST 16-week PBO-controlled Study Involving Oligoarticular PsA with Apremilast
Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligo...
The Burden of Oligoarticular PsA in the United States
Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan
Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis
Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial
